Ketamine Impacts Gut-Brain-Lung Axis for Health

Ketamine and the Gut-Brain-Lung Axis: A New Frontier for Mental and Systemic Health

Research published in Molecular Psychiatry by teams at Huazhong University of Science and Technology and Chiba University reveals ketamine’s effects extend far beyond the brain. The anesthetic and rapid-acting antidepressant interacts directly with gut microbiota, microbial metabolites, and intestinal immune cells to influence systemic inflammation and organ function. This work establishes the gut-brain-lung axis as a critical, modifiable pathway for neuropsychiatric and inflammatory diseases.

From Anesthetic to Antidepressant: Ketamine’s Established and Emerging Roles

Ketamine is a potent N-methyl-D-aspartate receptor (NMDAR) antagonist. Its primary medical uses have been for anesthesia and pain management. The discovery of its rapid antidepressant effects, often within hours for treatment-resistant depression, changed psychiatric practice. Its mechanism, however, was long thought to be solely through direct action on brain neurons. The 2026 review by Zhao, Zhang, Hashimoto, and colleagues synthesizes accumulating evidence that a significant portion of ketamine’s benefit, including its anti-inflammatory and organ-protective properties, is mediated through the gut.

“These gut-mediated pathways must be distinguished from ketamine’s well-established direct central and peripheral actions,” the authors state. This distinction is vital for understanding side effects and for developing more targeted therapies that separate therapeutic benefits from potential risks.

The Science of Ketamine’s Gut-Brain Communication

Ketamine’s influence on the gut-brain axis appears to be multi-faceted, involving microbial populations, their metabolic output, and the migration of immune cells from the intestines to the brain.

Restoring Microbial Balance and Short-Chain Fatty Acids

Studies in animal models link ketamine administration to a restoration of microbial balance, or eubiosis. This often involves an increase in beneficial bacterial taxa and a reduction in pro-inflammatory species. A key consequence is the normalization of short-chain fatty acid (SCFA) levels. SCFAs like butyrate, propionate, and acetate are fermentation products of dietary fiber with powerful anti-inflammatory and neuroprotective properties. Depleted SCFA levels are common in depression and neurodegenerative conditions. By supporting a microbiome that produces these metabolites, ketamine may help repair the gut environment. Dietary strategies like consuming prebiotic fiber aim for a similar metabolic outcome.

Halting the Migration of Gut-Derived Inflammatory Cells

A more direct immune pathway involves specific T-cells in the gut lining. The research highlights that ketamine is associated with “reduced migration of gut-derived γδ T17 and Th17 cells to the central nervous system.” These cell types are potent producers of the inflammatory cytokine IL-17. In conditions of intestinal permeability or “leaky gut,” these cells can travel via circulation to the brain, where they contribute to neuroinflammation—a consistent biological finding in major depression. This cell trafficking model provides a mechanistic link between intestinal integrity, systemic immunity, and mood. Therapeutic approaches for restoring intestinal permeability may complement this effect.

The net result of these gut-mediated actions is “attenuated neuroinflammation and depressive-like behaviors” in preclinical studies. This suggests a portion of ketamine’s rapid mood effect could stem from quickly calming an immune signal originating in the gut.

Enantiomer-Specific Effects: Arketamine vs. Esketamine

Ketamine exists as two mirror-image molecules, or enantiomers: (R)-ketamine (arketamine) and (S)-ketamine (esketamine). Esketamine is the form approved for treatment-resistant depression. The review points to important differences between them, particularly concerning the gut and side effects.

“Arketamine appears to provide more sustained neuroprotection and may be associated with fewer adverse effects than esketamine,” the authors note. While both forms show activity on the gut-brain axis, arketamine’s profile in animal studies suggests a potentially better therapeutic window with less dissociation and abuse liability. This has spurred ongoing clinical research into arketamine as a next-generation treatment. The differences underscore that not all “ketamine” effects are identical; the specific chemical structure determines interactions with both neural receptors and the gut ecosystem.

The Gut-Lung Axis: Ketamine’s Systemic Reach

The communication network extends to the lungs, forming a gut-brain-lung axis. In models of acute lung injury and systemic inflammation, ketamine has been reported to “limit bacterial translocation and mesenteric lymph-associated inflammatory signaling.” It also reduces pulmonary infiltration of pro-inflammatory cells.

Essentially, ketamine may help maintain intestinal barrier integrity during severe stress, preventing gut bacteria from entering circulation (translocation) and activating immune pathways that ultimately damage the lungs. This positions ketamine, and particularly its gut-modulating properties, as relevant for critical care medicine and respiratory disorders beyond its psychiatric use.

Practical Implications and Causal Considerations

The evidence is compelling but primarily from animal and in vitro studies. The authors of the review “critically evaluat[e] the evidence for causality in gut-organ communication.” In humans, establishing direct causality—proving that ketamine’s antidepressant effect works *because* it changes the microbiome—remains challenging. It is likely a synergistic effect: direct NMDA receptor blockade in the brain occurs concurrently with gut-mediated immunomodulation.

Actionable Insights for Gut and Mental Health

This research validates the gut-brain axis as a legitimate target for intervention. It supports several practical approaches:

1. Diet as Foundation: A diet rich in diverse fibers to produce SCFAs supports the same microbial environment ketamine appears to promote. This is a foundational strategy for long-term gut microbiome health.
2. Psychobiotic Potential: The role of specific bacteria in mood regulation is the focus of psychobiotics research. While not replacements for ketamine, specific probiotic strains may offer adjunctive support for mood by modulating similar inflammatory pathways.
3. Barrier Integrity: Maintaining a healthy intestinal barrier may prevent the migration of inflammatory cells. This involves managing stress, avoiding chronic NSAID overuse, and identifying individual food intolerances.
4. Personalized Medicine: Future treatment may involve profiling a patient’s microbiome and immune status to predict response to ketamine or to choose between its enantiomers.

It is also important to acknowledge ketamine’s limitations and risks. Potential side effects include dissociation, increased blood pressure, and, with repeated use, bladder toxicity and dependency. Its use is strictly controlled and requires medical supervision. The search for treatments that mimic its gut-brain benefits without these risks is a major goal.

Key Takeaways

• Ketamine’s therapeutic effects for depression and inflammation are partially mediated through the gut, not solely through direct brain action.
• Along the gut-brain axis, ketamine is associated with restoring microbial balance, normalizing beneficial short-chain fatty acids, and reducing the brainward migration of gut-derived inflammatory immune cells.
• The gut-lung axis is also modulated, suggesting relevance for critical care and respiratory conditions via protection of intestinal barrier function.
• The (R)-ketamine enantiomer (arketamine) may offer more sustained effects with fewer side effects than the currently approved (S)-ketamine (esketamine), based on preclinical data.
• While causal proof in humans is still needed, this research strongly supports targeting the gut microbiome and intestinal barrier as a strategy for supporting mental and systemic health.
• Dietary and probiotic strategies that enhance gut barrier integrity and SCFA production align with the biological pathways ketamine engages.
• Ketamine is a controlled substance with significant risks; its use must be managed by a qualified medical professional.

Sources:
https://pubmed.ncbi.nlm.nih.gov/41974884/
https://pubmed.ncbi.nlm.nih.gov/41967815/
https://pubmed.ncbi.nlm.nih.gov/41961405/

This article is for informational purposes only. Consult a qualified professional for personalised advice.